Cargando…

Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors

In this study, we report a series of newly synthesised sulphonamides of aziridine-2-carboxylic acid (Az-COOH) ester and amide analogues as potent protein disulphide isomerase (PDI, EC 5.3.4.1) inhibitors. The inhibitory activity on PDI was determined against recombinant human PDIA1 and PDIA3 protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Zelencova-Gopejenko, D., Andrianov, V., Domracheva, I., Kanepe-Lapsa, I., Milczarek, M., Stojak, M., Przyborowski, K., Fedak, F. A., Walczak, M., Kramkowski, K., Wietrzyk, J., Chlopicki, S., Kalvins, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120451/
https://www.ncbi.nlm.nih.gov/pubmed/37070480
http://dx.doi.org/10.1080/14756366.2022.2158187
_version_ 1785029182919540736
author Zelencova-Gopejenko, D.
Andrianov, V.
Domracheva, I.
Kanepe-Lapsa, I.
Milczarek, M.
Stojak, M.
Przyborowski, K.
Fedak, F. A.
Walczak, M.
Kramkowski, K.
Wietrzyk, J.
Chlopicki, S.
Kalvins, I.
author_facet Zelencova-Gopejenko, D.
Andrianov, V.
Domracheva, I.
Kanepe-Lapsa, I.
Milczarek, M.
Stojak, M.
Przyborowski, K.
Fedak, F. A.
Walczak, M.
Kramkowski, K.
Wietrzyk, J.
Chlopicki, S.
Kalvins, I.
author_sort Zelencova-Gopejenko, D.
collection PubMed
description In this study, we report a series of newly synthesised sulphonamides of aziridine-2-carboxylic acid (Az-COOH) ester and amide analogues as potent protein disulphide isomerase (PDI, EC 5.3.4.1) inhibitors. The inhibitory activity on PDI was determined against recombinant human PDIA1 and PDIA3 proteins using an insulin reduction assay. These compounds in low micromolar to low nanomolar concentrations showed the effective in vitro inhibitory properties of PDIA1 with weaker effects on PDIA3. Complexes of (15)N- and (15)N,(13)C- uniformly labelled recombinant human PDIA1a with two PDIA1 inhibitors were produced and investigated by a protein nuclear magnetic resonance (NMR) spectroscopy. It was found that both C53 and C56 of the PDIA1 enzyme were involved in covalent binding. Finally, in a range of pharmacological studies, we demonstrated that investigated compounds displayed anti-cancer and anti-thrombotic activity. These findings demonstrate that sulphonamides of Az-COOH derivatives are promising candidates for the development of novel anti-cancer and anti-thrombotic agents.
format Online
Article
Text
id pubmed-10120451
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-101204512023-04-22 Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors Zelencova-Gopejenko, D. Andrianov, V. Domracheva, I. Kanepe-Lapsa, I. Milczarek, M. Stojak, M. Przyborowski, K. Fedak, F. A. Walczak, M. Kramkowski, K. Wietrzyk, J. Chlopicki, S. Kalvins, I. J Enzyme Inhib Med Chem Research Paper In this study, we report a series of newly synthesised sulphonamides of aziridine-2-carboxylic acid (Az-COOH) ester and amide analogues as potent protein disulphide isomerase (PDI, EC 5.3.4.1) inhibitors. The inhibitory activity on PDI was determined against recombinant human PDIA1 and PDIA3 proteins using an insulin reduction assay. These compounds in low micromolar to low nanomolar concentrations showed the effective in vitro inhibitory properties of PDIA1 with weaker effects on PDIA3. Complexes of (15)N- and (15)N,(13)C- uniformly labelled recombinant human PDIA1a with two PDIA1 inhibitors were produced and investigated by a protein nuclear magnetic resonance (NMR) spectroscopy. It was found that both C53 and C56 of the PDIA1 enzyme were involved in covalent binding. Finally, in a range of pharmacological studies, we demonstrated that investigated compounds displayed anti-cancer and anti-thrombotic activity. These findings demonstrate that sulphonamides of Az-COOH derivatives are promising candidates for the development of novel anti-cancer and anti-thrombotic agents. Taylor & Francis 2023-04-18 /pmc/articles/PMC10120451/ /pubmed/37070480 http://dx.doi.org/10.1080/14756366.2022.2158187 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Research Paper
Zelencova-Gopejenko, D.
Andrianov, V.
Domracheva, I.
Kanepe-Lapsa, I.
Milczarek, M.
Stojak, M.
Przyborowski, K.
Fedak, F. A.
Walczak, M.
Kramkowski, K.
Wietrzyk, J.
Chlopicki, S.
Kalvins, I.
Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors
title Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors
title_full Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors
title_fullStr Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors
title_full_unstemmed Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors
title_short Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors
title_sort aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel pdia1 and pdia3 inhibitors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120451/
https://www.ncbi.nlm.nih.gov/pubmed/37070480
http://dx.doi.org/10.1080/14756366.2022.2158187
work_keys_str_mv AT zelencovagopejenkod aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT andrianovv aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT domrachevai aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT kanepelapsai aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT milczarekm aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT stojakm aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT przyborowskik aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT fedakfa aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT walczakm aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT kramkowskik aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT wietrzykj aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT chlopickis aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors
AT kalvinsi aromaticsulphonamidesofaziridine2carboxylicacidderivativesasnovelpdia1andpdia3inhibitors